CRMD (CorMedix Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CRMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Kaufman Beth Zelnick | Chief Legal Officer | F | — | — |
| 2026-09-01 | Susan Blum | Chief Financial Officer | F | — | — |
| 2026-09-01 | Elizabeth Hurlburt | Chief Operating Officer | F | — | — |
| 2026-02-06 | Joseph Todisco | Chief Executive Officer | A | — | — |
| 2026-02-06 | Elizabeth Hurlburt | Chief Operating Officer | A | — | — |
| 2026-02-06 | Kaufman Beth Zelnick | Chief Legal Officer | A | — | — |
| 2026-01-27 | ALAN W DUNTON | Director | A | — | — |
| 2026-01-27 | Joseph Todisco | Chief Executive Officer | MIXED | — | — |
| 2026-01-27 | Kaufman Beth Zelnick | Chief Legal Officer | MIXED | — | — |
| 2026-01-27 | Gregory Scott Duncan | Director | A | — | — |
| 2026-01-27 | Robert A Stewart | Director | A | — | — |
| 2026-01-27 | Janet Dillione | Director | A | — | — |
| 2026-01-27 | Myron Kaplan | Director | A | — | — |
| 2026-01-27 | Susan Blum | Chief Financial Officer | MIXED | — | — |
| 2026-01-27 | Elizabeth Hurlburt | Chief Operating Officer | MIXED | — | — |
| 2026-01-27 | Steven W Lefkowitz | Director | A | — | — |
| 2026-01-22 | Janet Dillione | Director | Sell | — | — |
| 2026-01-20 | Elizabeth Hurlburt | Chief Operating Officer | F | — | — |
| 2026-01-20 | Joseph Todisco | Chief Executive Officer | MIXED | — | — |
| 2026-01-15 | Michael David Seckler | Chief Commercial Officer | A | — | — |
| 2026-01-14 | Steven W Lefkowitz | Director | M | — | — |
| 2026-01-06 | Kaufman Beth Zelnick | Chief Legal Officer | F | — | — |
| 2026-01-06 | Elizabeth Hurlburt | Chief Operating Officer | F | — | — |
| 2026-01-02 | ALAN W DUNTON | Director | MIXED | — | — |
| 2025-12-19 | Joseph Todisco | Chief Executive Officer | MIXED | — | — |
| 2025-12-11 | Janet Dillione | Director | MIXED | — | — |
| 2025-12-10 | Steven W Lefkowitz | Director | Sell | — | — |
| 2025-12-04 | Janet Dillione | Director | MIXED | — | — |
| 2025-11-26 | Janet Dillione | Director | MIXED | — | — |
| 2025-11-18 | Janet Dillione | Director | Sell | — | — |
| 2025-10-27 | Myron Kaplan | Director | Buy | — | — |
| 2025-09-18 | Gregory Scott Duncan | Director | M | — | — |
| 2025-09-16 | ALAN W DUNTON | Director | MIXED | — | — |
| 2025-09-12 | Joseph Todisco | Chief Executive Officer | F | — | — |
| 2025-09-12 | Joseph Todisco | Chief Executive Officer | MIXED | — | — |
| 2025-09-11 | Kaufman Beth Zelnick | Chief Legal Officer | MIXED | — | — |
| 2025-09-11 | Elizabeth Hurlburt | Chief Operating Officer | MIXED | — | — |
| 2025-09-08 | Kaufman Beth Zelnick | Chief Legal Officer | F | — | — |
| 2025-09-08 | Elizabeth Hurlburt | Chief Operating Officer | F | — | — |
| 2025-09-03 | Elizabeth Hurlburt | Chief Operating Officer | A | — | — |
| 2025-09-03 | Susan Blum | Chief Financial Officer | A | — | — |
| 2025-09-03 | Kaufman Beth Zelnick | Chief Legal Officer | A | — | — |
| 2025-04-03 | Steven W Lefkowitz | Director | M | — | — |
| 2025-04-02 | Joseph Todisco | Chief Executive Officer | M | — | — |
| 2025-01-22 | ALAN W DUNTON | Director | A | — | — |
| 2025-01-22 | Myron Kaplan | Director | A | — | — |
| 2025-01-22 | Joseph Todisco | Chief Executive Officer | MIXED | — | — |
| 2025-01-22 | Gregory Scott Duncan | Director | A | — | — |
| 2025-01-22 | Robert A Stewart | Director | A | — | — |
| 2025-01-22 | Steven W Lefkowitz | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 774,749 | — |
| — | Director | 533,774 | — |
| — | Chief Operating Officer | 270,463 | — |
| — | Chief Legal Officer | 260,684 | — |
| — | Director | 241,487 | — |
| — | Director | 160,930 | — |
| — | Chief Commercial Officer | 133,156 | — |
| — | Director | 127,951 | — |
| — | Chief Financial Officer | 124,315 | — |
| — | EVP, Chief Commercial Officer | 100,992 | — |
| — | Exec VP of Tech Operations | 96,878 | — |
| — | Chief Financial Officer | 95,270 | — |
| — | Chief Executive Officer | 80,654 | — |
| — | Director | 70,703 | — |
| — | Director | 68,926 | — |
| — | Director | 68,786 | — |
| — | Director | 66,453 | — |
| — | Chief Executive Officer | 60,905 | — |
| — | Director | 36,474 | — |
| — | Chief Financial Officer | 27,517 | — |
| — | Director | 10,000 | — |
| — | Director | 7,420 | — |
| — | General Counsel | 7,200 | — |
| — | Director | 5,714 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRMD quote page; the site-wide leaderboard is on the insider transactions hub.